RB1 and ovarian carcinoma: Both ovarian carcinoma models showed reductions in Rb phosphorylation and cyclin A2 in tumor tissue at the experimental endpoint (between 44 and 54 days of treatment), sustained up to 16 hours after the final dose was administered (Fig. 2F).